Glaxo Smith Kline (GSK) announced in May that Flovent HFA, a metered-dose inhaler, as well as Flovent Diskus, a dry powder inhaler, would be discontinued as of Dec. 31, 2023. Experts weigh in.

The other single-inhaler on the market for COPD triple therapy, fluticasone-umeclidinium-vilanterol, is a dry-powder inhaler that does not contain hydrofluoroalkane-134a.

The Dry Powder Inhaler Market is poised for significant growth, with a market value of USD 20.83 billion in 2024, projected to climb to USD 29.95 billion by 2034, representing a steady CAGR of 3. ...

Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD Provided by GlobeNewswire Jun 2, 2025, 10:30:00 AM ...

Aptar Pharma pulled the trigger on a deal for Pharmaxis’ Orbital high payload dry powder inhaler technology, ... Aptar paid $250,000 to secure a 12-month window in which to assess the commercial ...

The dry powder inhaler market is projected to be worth USD 20.83 billion in 2024. The market is likely to reach USD 29.95 billion by 2034. The Industry is expected to surge at a CAGR of 3.70% from ...

As the rush to exit commercial real-estate funds goes mainstream, more Main Street funds are putting up gates to limit withdrawals The plight of investors looking to pull money out of commercial ...

Liquidia has completed the INSPIRE trial (NCT03399604), or Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil, an open-label, multi-center phase 3 clinical study of ...

In an emergency, an inhaler can save a life. But the gas it releases contributes to global warming. Each of the most commonly prescribed inhalers has about the same climate warming impact as ...

Liquidia announces FDA approval and commercial launch of YUTREPIA for treating pulmonary arterial hypertension and PH-ILD. Quiver AI Summary. Liquidia Corporation has announced that its inhalation ...

Liquidia has completed the INSPIRE trial (NCT03399604), or Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil, an open-label, multi-center phase 3 clinical study ...